It is widely believed that in elderly at risk for AD, reductions in the cerebrospinal fluid (CSF) levels of amyloid beta 1–42 (Aβ42), which are associated with brain amyloid deposition [1,2], precede elevations in CSF tau levels, a marker of neurodegeneration [3]. This evidence concerns the gene MAPT and Alzheimer disease.